{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061122","form_type":"8-K","ticker":"OFIX","cik":"0000884624","company_name":"Orthofix Medical Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.247446+00:00","generated_at":"2026-06-08T12:27:12.152126+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Orthofix Q3 net sales $184M (+61% reported, +8% pro forma); GAAP EPS -$0.77, adj. $0.07","bullets":["Net sales $184M, +61% reported, +8% pro forma (excl. one-time stocking order); Bone Growth Therapies +15%.","GAAP net loss $28.9M ($0.77/share); adjusted net income $2.7M ($0.07/share); adjusted EBITDA $13.5M (7.3% of sales).","Entered new $150M financing agreement (Nov 6, 2023), replaced prior $175M revolver; cash $33.7M at Sep 30.","Updated 2023 net sales guidance lowered to $739M-$744M (prev $752M-$758M); adjusted EBITDA guidance unchanged $42M-$46M.","Management transition: Catherine Burzik (Chair) as Interim CEO after board investigation led to departure of three former executives."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061122","json":"https://secwatch.observer/filing/0000950170-23-061122.json","markdown":"https://secwatch.observer/filing/0000950170-23-061122.md","text":"https://secwatch.observer/filing/0000950170-23-061122.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/884624/000095017023061122/0000950170-23-061122-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/884624/000095017023061122/ofix-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T12:27:12.152126+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f0b9703f0c2ec6542d7d32544e695df673393b26","claim":"Orthofix Medical Inc. reported the quarter ended September 30, 2023 results: revenue $184.0 million, net income Net loss was $(28.9) million, EPS $(0.77). Guidance reaffirmed.","evidence_excerpt":"Net sales were $184.0 million, earnings per share (“EPS”) was $(0.77), and adjusted EPS was $0.07.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/884624/000095017023061122/0000950170-23-061122-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$184.0 million"},{"label":"Net income","value":"Net loss was $(28.9) million"},{"label":"EPS","value":"$(0.77)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}